|
Outlook Therapeutics Inc (OTLK) |
|
Outlook Therapeutics Inc
OTLK's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Outlook Therapeutics Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.58 %
Outlook Therapeutics Inc realized net income compared to net loss a year ago in III. Quarter 2024
• More on OTLK's Growth
|
|
Outlook Therapeutics Inc realized a net loss in trailing twelve months.
Outlook Therapeutics Inc realized cash reduction of $ -0.07 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.86.
• More on OTLK's Valuation
|
|
|
|
|
Outlook Therapeutics Inc realized net loss in trailing twelve months.
Outlook Therapeutics Inc realized cash outflow of $ -0.07per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.86.
• More on OTLK's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com